Value of PASI90 Versus Merit-Based Incentive Payment System Efficacy Measures
{{output}}
Background: Achieving ≥90% improvement in Psoriasis Area and Severity Index (PASI90) is achievable with newer biologic therapies, such as ixekizumab. Standard of care payment systems such as the Merit-based Incentive Payment Sys... ...
